In this article, we will list the 5 Best Penny Stocks That Could Triple Your Money. Please visit 10 Best Penny Stocks That Could Triple Your Money if you’d like to see an extended list and how we came up with the list of best penny stocks.
5. ProKidney Corp. (NASDAQ:PROK)
ProKidney Corp. (NASDAQ:PROK) is one of the 10 best penny stocks that could triple your money.
On March 19, ProKidney Corp. (NASDAQ:PROK) announced fourth-quarter revenue of $893,000 against consensus estimates of $600,000. The company provided updates on its clinical progress and strategic priorities for advancing rilparencel through regulatory pathways.
Image: Depositphotos
Chief Executive Officer Bruce Culleton stated that 2025 had been an important year for the company, marked by the positive Phase 2 study for REGEN-007, alignment with the FDA on the accelerated approval pathway for rilparencel, and robust enrollment for the Phase 3 PROACT 1 study.
The company is well-positioned to achieve upcoming key milestones, including the completion of the enrolment for the Phase 3 PROACT 1 study this year and the pivotal eGFR slope data from the study in the second quarter of 2027. Culleton stated:
“Our mission remains highly focused on bringing a potential new treatment option to patients with advanced CKD and diabetes at high risk of kidney failure – an area of high unmet medical need.”
The company continues to advance its development program to address gaps in chronic kidney disease treatment.
ProKidney Corp. (NASDAQ:PROK) is engaged in developing cell therapies for the treatment of chronic kidney diseases. Its product portfolio includes rilparencel which is in Phase III of clinical trial. Alongside this, the company is developing different cryopreserved versions of rilparencel, with each one in a different phase of clinical trials.
4. Coherus Oncology Inc. (NASDAQ:CHRS)
Coherus Oncology Inc. (NASDAQ:CHRS) is one of the 10 best penny stocks that could triple your money.
On March 10, Coherus Oncology Inc. (NASDAQ:CHRS) reported its fourth quarter EPS of (34c) above the street consensus of (31c), while revenue came in at $12.8 million versus $14.1 million expected.
The company highlighted strong progress in 2025, including a significant increase in LOQTORZI sales and a major reduction in debt levels. Management emphasized its transition toward an oncology-focused business, supported by growing revenues, potential partnership opportunities, and a pipeline with multiple clinical catalysts expected in 2026. Commenting on the update, Coherus chairman and CEO, Denny Lanfear, stated:
“We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative oncology company focused on overcoming immune resistance in cancer. At the same time, we continued to reduce our overall debt since its peak in 2024 by over 90% to $38.8 million, we are now strategically positioned with growing revenues from our foundational PD-1 inhibitor, potential deal opportunities across the portfolio and geographies, and two promising pipeline candidates with multiple 2026 clinical readouts.”
Coherus Oncology Inc. (NASDAQ:CHRS) works on immunotherapies to treat cancer. Its product portfolio includes UDENYCA, LOQTORZI, Casdozokitug, and CHS-114. It also has various agreements, including a collaboration agreement, license agreements, and out-licensing agreements with different companies.
3. Vertical Aerospace Ltd. (NYSE:EVTL)
Vertical Aerospace Ltd. (NYSE:EVTL) is one of the 10 best penny stocks that could triple your money.
On March 24, Vertical Aerospace Ltd. (NYSE:EVTL) held its fourth quarter 2025 earnings call and full-year business strategy update. The company’s progress on its Valo electric vertical takeoff and landing (eVTOL) aircraft development and certification plan was discussed by Chairman Domhnal Slattery.
Slattery emphasized that Vertical Aerospace is conducting piloted flight tests of its full-scale Valo prototype for 20 months, and pilot transition tests are going well under the oversight of the UK Civil Aviation Authority. The company is close to completing the transition flight test phase, methodically progressing towards the closure of the range between hover and wing-borne flight modes.
Slattery also admitted that the company is continuing to explore opportunities for capital raising across capital markets, strategic partners, and government support for the route through certification. Chief Engineer David King stated:
“We are nearing completion of the transition flight test phase, and the data we are collecting each flight is directly informing certification of our final commercial design. By working closely with the CAA upfront, we now have a clear, well-defined, tried and tested path to certification.”
Vertical Aerospace Ltd. (NYSE:EVTL) is an aerospace technology company that designs and manufactures zero-emission electric vertical takeoff and landing (eVTOL) aircraft. Through its flagship VX4 aircraft, the company is on a mission to advance air mobility and make urban travel more sustainable.
2. OmniAb Inc. (NASDAQ:OABI)
OmniAb Inc. (NASDAQ:OABI) is one of the 10 best penny stocks that could triple your money.
On March 5, OmniAb Inc. (NASDAQ:OABI) reported fourth-quarter revenue of $8.4 million, coming in below consensus estimates of $9.0 million. The company closed 2025 with a growing base of 107 active partners and a growing portfolio consisting of 407 active programs.
The company’s Chief Executive Officer, Matt Foehr, mentioned that the company’s differentiated technologies underpin its business outlook and enable it to grow the partner base while maintaining a disciplined cost structure. As the partner pipeline moves forward, some assets are emerging that have the potential to drive material milestones and recurring royalty revenue. Shedding light on the recent launch and the company’s drive towards innovation, Foehr stated:
“Our focus on innovation was evident in the recent launch of OmniUltra(TM), which strengthens our ability to attract new partners and service new programs. Additionally, we continue to see strong interest in the xPloration partner access program and are excited about its contributions to the business.”
OmniAb Inc. (NASDAQ:OABI) provides licenses to pharmaceutical and biotech companies for discovery research technology around various parts of the world. To find the best antibodies and other target-binding proteins for partners’ drug development efforts, the company’s technology platform creates and screens diverse antibody repertoires. Animal-based technologies are also offered by the company.
1. Ocugen Inc. (NASDAQ:OCGN)
Ocugen Inc. (NASDAQ:OCGN) is one of the 10 best penny stocks that could triple your money.
On March 24, Ocugen Inc. (NASDAQ:OCGN) announced 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410, its modifier gene therapy for geographic atrophy secondary to dry age-based macular degeneration.
Some key findings from Phase 2 have included a 31% reduction in lesion growth in the optimal dose group compared with the control group. They also incorporated a 27% slower rate of ellipsoid zone loss compared to control, indicating a preservation of structure within the retina, and a 55% response rate for patients treated with OCU410, with a reduction in lesion size of 30% compared to control.
The Phase 2 clinical trial follows on from the clean safety data observed in Phase 1, with no serious adverse events related to OCU410 observed and with no endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy observed to date. Ocugen aims to start the OCU410 Phase 3 registrational trial in the third quarter of 2026, in line with the company’s ambition to submit three BLA filings in three years.
On March 11, Lucid Capital analyst Elemer Piros increased the firm’s price target on Ocugen Inc. (NASDAQ:OCGN) from $15 to $22, while maintaining his Buy rating on the shares. The move follows the company’s announcement of positive preliminary Phase 2 data for its OCU410 therapy, supporting growing confidence in its potential in treating geographic atrophy.
Ocugen Inc. (NASDAQ:OCGN) works on vaccines, biologics, and novel gene and cell therapies that enhance patients’ health. Its product portfolio includes various products, including OCU400 under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of Leber congenital amaurosis, OCU410 and OCU410ST both in Phase 1/2, OCU200 and NeoCart OCU500, OCU510, and OCU520.
While we acknowledge the potential of OCGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OCGN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
